MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
The Claude ban is a crash course in digital resilience — and that’s good for Hong Kong bankers
Getting governance right in Hong Kong’s regulatory environment